
Transtema - Weak Q1 – We Expect Improvements from Here

Redeye maintains a positive view of Transtema despite a weak Q1 and cuts in Base Case and forecasts. However, we see several reasons to believe Transtema is on a path to improved profitability from now on and back to organic growth in 2025.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Transtema - Weak Q1 – We Expect Improvements from Here](#)